Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone

Boston, MA 10/09/2014 (wallstreetpr) – Ocular Therapeutix Inc (NASDAQ:OCUL) said that it has completed the process of enrollment for its two Stage three clinical studies on investigating Sustained Release Dexamethasone or OTOX-DP. The company indicated that the study was meant to treat ocular pain and inflammation after a surgery of cataract. One-Time Administration The company […]